While sparsentan blocks both ETA and AT1 receptors, atrasentan (Vanrafia) is a targeted therapy that ...
Several oral and injectable medications have also been approved to help manage atopic dermatitis symptoms ...
When your first-line CIDP treatment stops improving your symptoms, your provider may try another primary ...
For people living with primary immunodeficiency (PI) , immunoglobulin replacement therapy (Ig) is a cornerstone ...
Your individual CIDP treatment plan will depend on factors such as symptom severity, nerve damage, ...
Photothermal reversibility characterization of lysozyme flexible fibrils (FFs) nanoNETs Atomic force microscopy (AFM) images (Fig. 2a ...
Deletion of the SPPL3 sheddase improves allogeneic CAR T cell persistence. ...
For more than 20 years, menopausal hormone therapy carried the U.S. Food and Drug Administration’s ...